Literature DB >> 25117686

Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma.

Sonali Setua1, Myriam Ouberai, Sara G Piccirillo, Colin Watts, Mark Welland.   

Abstract

Glioblastoma multiforme (GBM) remains the most aggressive and challenging brain tumour to treat. We report the first successful chemo-radiotherapy on patient derived treatment resistant GBM cells using a cisplatin-tethered gold nanosphere. After intracellular uptake, the nanosphere effects DNA damage which initiates caspase-mediated apoptosis in those cells. In the presence of radiation, both gold and platinum of cisplatin, serve as high atomic number radiosensitizers leading to the emission of ionizing photoelectrons and Auger electrons. This resulted in enhanced synergy between cisplatin and radiotherapy mediated cytotoxicity, and photo/Auger electron mediated radiosensitisation leading to complete ablation of the tumour cells in an in vitro model system. This study demonstrates the potential of designed nanoparticles to target aggressive cancers in the patient derived cell lines providing a platform to move towards treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25117686     DOI: 10.1039/c4nr03693j

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  26 in total

1.  Nanoparticle-Mediated X-Ray Radiation Enhancement for Cancer Therapy.

Authors:  Autumn D Paro; Ilanchezhian Shanmugam; Anne L van de Ven
Journal:  Methods Mol Biol       Date:  2017

2.  Enhancement of low-energy electron emission in 2D radioactive films.

Authors:  Alex Pronschinske; Philipp Pedevilla; Colin J Murphy; Emily A Lewis; Felicia R Lucci; Garth Brown; George Pappas; Angelos Michaelides; E Charles H Sykes
Journal:  Nat Mater       Date:  2015-06-15       Impact factor: 43.841

3.  Toxicity of antimony, copper, cobalt, manganese, titanium and zinc oxide nanoparticles for the alveolar and intestinal epithelial barrier cells in vitro.

Authors:  T Titma; R Shimmo; J Siigur; A Kahru
Journal:  Cytotechnology       Date:  2016-10-19       Impact factor: 2.058

4.  Probabilistic modelling of prospective environmental concentrations of gold nanoparticles from medical applications as a basis for risk assessment.

Authors:  Indrani Mahapatra; Tian Yin Sun; Julian R A Clark; Peter J Dobson; Konrad Hungerbuehler; Richard Owen; Bernd Nowack; Jamie Lead
Journal:  J Nanobiotechnology       Date:  2015-12-22       Impact factor: 10.435

5.  Low-cost, rapidly-developed, 3D printed in vitro corpus callosum model for mucopolysaccharidosis type I.

Authors:  Anthony Tabet; Matthew Gardner; Sebastian Swanson; Sydney Crump; Austin McMeekin; Diana Gong; Rebecca Tabet; Benjamin Hacker; Igor Nestrasil
Journal:  F1000Res       Date:  2016-12-02

Review 6.  Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma.

Authors:  Amy Lee Bredlau; Suraj Dixit; Chao Chen; Ann-Marie Broome
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy.

Authors:  Weiwei Qin; Guan Huang; Zuanguang Chen; Yuanqing Zhang
Journal:  Front Pharmacol       Date:  2017-01-18       Impact factor: 5.810

8.  Cold Atmospheric Plasma Induces ATP-Dependent Endocytosis of Nanoparticles and Synergistic U373MG Cancer Cell Death.

Authors:  Zhonglei He; Kangze Liu; Eline Manaloto; Alan Casey; George P Cribaro; Hugh J Byrne; Furong Tian; Carlos Barcia; Gillian E Conway; Patrick J Cullen; James F Curtin
Journal:  Sci Rep       Date:  2018-03-28       Impact factor: 4.379

9.  Effects of nanoparticle size on antitumor activity of 10-hydroxycamptothecin-conjugated gold nanoparticles: in vitro and in vivo studies.

Authors:  Hanmei Bao; Qing Zhang; Hui Xu; Zhao Yan
Journal:  Int J Nanomedicine       Date:  2016-03-07

Review 10.  Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells.

Authors:  Yan Liu; Pengcheng Zhang; Feifei Li; Xiaodong Jin; Jin Li; Weiqiang Chen; Qiang Li
Journal:  Theranostics       Date:  2018-02-12       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.